Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01090492 · ClinicalTrials.gov registry record · Phase 2
PF-00489791 For The Treatment Of Raynaud's
A Phase 2 study of Peripheral Vascular Disease and Raynaud's Disease, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 243
- Enrollment target
- 20
- Study locations
NCT01090492 is a Phase 2 study of Peripheral Vascular Disease and Raynaud's Disease that has completed, run by Pfizer. The registered enrollment target is 243 participants, below the 273-participant average among 25 other Peripheral Vascular Disease trials with a reported enrollment target (11% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT01090492, a Phase 2 study of Peripheral Vascular Disease and Raynaud's Disease, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 243 participants
- Enrollment target
- 20
- Study locations
Study Summary
The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
Conditions Studied
Interventions
- DRUG PF-00489791
Study Locations (20)
Michigan
- University of Michigan - Ann Arbor
- University of Michigan Health System - Ann Arbor
- West Michigan Rheumatology, PLLC - Grand Rapids
New York
- The Center for Rheumatology - Albany
- Regional Rheumatology Associates - Binghamton
- AAIR Research Center - Rochester
Indiana
- Diagnostic Rheumatology and Research, PC - Indianapolis
- Memorial Health System, Inc. dba Memorial Medical Group Clinical Research Institute - South Bend
Maryland
- Johns Hopkins University - Division of Rheumatology - Baltimore
- The Center for Rheumatology and Bone Research - Wheaton
Pennsylvania
- East Penn Rheumatology Associates, PC - Bethlehem
- Altoona Center for Clinical Research - Duncansville
California
- Stanford Hospital and Outpatient Center - Redwood City
Connecticut
- University of Connecticut Health Center - Farmington
District of Columbia
- Georgetown University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2010-08-04 |
| Est. Completion | 2011-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01090492
The ClinicalTrials.gov registry entry for NCT01090492 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 273-participant average among 25 other Peripheral Vascular Disease trials with a reported enrollment target (11% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Peripheral Vascular Disease appearing as the primary indexed condition, and to 1 intervention - of which PF-00489791 is the first listed.
NCT01090492 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Michigan, New York, Indiana.
Frequently Asked Questions
What is clinical trial NCT01090492 about?
NCT01090492 is a clinical study titled "PF-00489791 For The Treatment Of Raynaud's". The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
What is the current status of trial NCT01090492?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 243 participants. The study started on 2010-08-04. Estimated completion is 2011-05-31.
What conditions does trial NCT01090492 study?
This clinical trial studies the following conditions: Peripheral Vascular Disease, Raynaud's Disease.
What interventions are being tested in trial NCT01090492?
The interventions under investigation include: PF-00489791 (DRUG).
Who is sponsoring clinical trial NCT01090492?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01090492 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Vascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication
COMPLETED · Phase 2
-
Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease
COMPLETED · Phase 2
-
Improving Mobility After Revascularization in Peripheral Artery Disease
RECRUITING · Phase 3
-
Far Red Light to Improve Functioning in PAD
RECRUITING · NA
-
Leg Exercise Assistive Paddling (LEAP) Therapy for Peripheral Artery Disease
RECRUITING · NA
-
ENhancing Exercise with LIGHT to Improve Functioning in PAD
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.